[CBYL] Carbylan Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.68 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CBYL

Refresh chart

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities3.51 M Cash From Investing Activities-180 K Cash From Operating Activities-4.05 M Gross Profit
Net Profit-5.18 M Operating Profit-4.9 M Total Assets7.71 M Total Current Assets4.31 M
Total Current Liabilities11.01 M Total Debt10 M Total Liabilities17.12 M Total Revenue10 K
Technical Data
High 52 week4.11 Low 52 week0.44 Last close0.68 Last change-1.31%
RSI75.91 Average true range0.06 Beta2.07 Volume
Simple moving average 20 days25.97% Simple moving average 50 days34.54% Simple moving average 200 days5.61%
Performance Data
Performance Week15.08% Performance Month35.8% Performance Quart17.88% Performance Half-32.1%
Performance Year-80.87% Performance Year-to-date-81.24% Volatility daily5.95% Volatility weekly13.31%
Volatility monthly27.28% Volatility yearly94.51% Relative Volume0% Average Volume367.78 K
New High New Low

News

2017-02-15 08:40:01 | KalVista Pharmaceuticals KALV in Focus: Stock Jumps 6%

2017-01-19 11:14:00 | Pittsburgh Law Office of Alfred G. Yates Jr., PC Announces Investigation of Carbylan Therapeutics, Inc. CBYL, currently known as KalVista Pharmaceuticals, Inc. KALV

2016-11-23 17:28:53 | KALVISTA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisit

2016-11-22 08:33:16 | KalVista Pharmaceuticals Announces Closing of Merger with Carbylan Therapeutics

2016-11-21 16:07:43 | CARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders

2016-11-14 13:02:09 | ETFs with exposure to Carbylan Therapeutics, Inc. : November 14, 2016

2016-11-11 11:59:30 | Carbylan Therapeutics, Inc. :CBYL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016

2016-11-09 15:28:47 | Carbylan Therapeutics reports 3Q loss

2016-11-08 16:18:36 | CARBYLAN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report

2016-11-04 16:08:57 | CARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Other Events

2016-10-14 10:28:48 | ETF’s with exposure to Carbylan Therapeutics, Inc. : October 14, 2016

2016-10-04 09:45:19 | ETF’s with exposure to Carbylan Therapeutics, Inc. : October 4, 2016

2016-09-30 16:10:22 | CARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Other Events

2016-09-23 10:04:14 | ETF’s with exposure to Carbylan Therapeutics, Inc. : September 23, 2016

2016-09-23 07:52:00 | Carbylan Shareholder CBYL Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Continues its Investigation of Carbylan Therapeutics, Inc.; Encourages Investors to Contact the Firm

2016-09-09 10:32:04 | ETF’s with exposure to Carbylan Therapeutics, Inc. : September 9, 2016

2016-08-29 11:11:28 | ETF’s with exposure to Carbylan Therapeutics, Inc. : August 29, 2016

2016-08-20 13:04:22 | CARBYLAN THERAPEUTICS, INC. Financials

2016-08-17 13:08:09 | ETF’s with exposure to Carbylan Therapeutics, Inc. : August 17, 2016

2016-08-16 10:04:04 | Carbylan Therapeutics, Inc. :CBYL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 16, 2016

2016-08-12 16:19:54 | CARBYLAN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report

2016-07-29 16:07:32 | CARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or

2016-06-28 16:13:15 | CARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement

2016-06-24 16:21:24 | CARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhi

2016-06-22 16:48:42 | CARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhi

2016-06-17 06:04:36 | CARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders

2016-06-15 10:45:22 | Why Best Buy, Celgene, and Three Other Stocks Are Making Headlines Today

2016-06-15 07:39:09 | Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement

2016-06-07 17:30:45 | ETF’s with exposure to Carbylan Therapeutics, Inc. : June 7, 2016

2016-06-06 12:13:45 | Carbylan Therapeutics, Inc. :CBYL-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016

2016-06-01 13:14:00 | Robbins Arroyo LLP is Investigating the Officers and Directors of Carbylan Therapeutics, Inc. CBYL on Behalf of Shareholders

2016-05-20 20:01:00 | Shareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigations of; NewLink Genetics Corporation, DeVry Education Group, Inc., Target Corporation, La Quinta Holdings Inc and Carbylan Therapeutics, Inc.; Encourages Investors to Contact the Firm

2016-04-22 09:20:00 | Get The Jump On Next Week With These 4 Trending Small Cap Stocks

2016-04-21 13:07:00 | Penny Stocks to Watch on Thursday April 21

2016-04-15 10:15:00 | Trade These 5 Breakout Stocks for Big Gains

2016-04-15 07:47:57 | Carbylan Therapeutics Announces Decision to Pursue Strategic Transaction

2016-02-01 16:12:50 | Carbylan Therapeutics Reports Top-Line Results From COR1.1 Clinical Trial of Hydros-TA in Patients With OA of the Knee